Fox Christine 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
TEVA (TEVA) EVP Christine Fox Sells Shares to Cover Taxes
What Happened
Christine Fox, Executive Vice President, U.S. Commercial of Teva Pharmaceutical Industries (TEVA), had 17,819 restricted share units (RSUs) vest on March 5, 2026 and those RSUs converted into ordinary shares. On the same day she sold 7,924 of those shares in open-market transactions for a weighted average price of $31.67, generating $250,940 in proceeds. The vesting/conversion is reported as a derivative exercise/conversion (Form 4 code M); some shares were also used/withheld to satisfy tax-withholding obligations.
Key Details
- Transaction date (period of report): March 5, 2026; Form 4 filed March 9, 2026 (appears timely).
- Sale: 7,924 shares sold at a weighted average price of $31.67; total proceeds $250,940. Sales occurred at prices ranging $31.26–$32.34 (weighted avg reported).
- Vesting/conversion: 17,819 RSUs vested/converted into ordinary shares on March 5, 2026 (reported as derivative exercise/conversion).
- Tax withholding: Footnotes indicate shares were sold/withheld to cover tax withholding related to the RSU vesting.
- 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Fox on August 11, 2025.
- Shares owned after the reported transactions: not specified in the provided filing excerpt.
Context
- This appears to be a routine "sell to cover" tied to RSU vesting (conversion of restricted units into shares and sale of some to meet tax obligations), not an ad hoc open-market sale unrelated to compensation.
- Code M (exercise/conversion of a derivative/security) here reflects RSU settlement (no exercise price). The presence of a 10b5-1 plan means the sale followed a pre-established trading plan.
Insider Transaction Report
Form 4
Fox Christine
EVP, U.S. Commercial
Transactions
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+17,819→ 92,829 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-05$31.67/sh−7,924$250,940→ 84,905 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-05−17,819→ 53,459 total→ Ordinary Shares (17,819 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2025, with 17,819 vested on March 5, 2026, 17,819 vesting on each of March 5, 2027 and March 5, 2028, and 17,821 vesting on March 5, 2029.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Christine Fox|2026-03-09